Drugs by condition
Drugs approved for achondroplasia
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
2
Still marketed, NDA or BLA
Drug classes
1
Novel drugs
2
New molecular entities and new biologics
In development
6
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for achondroplasia.
All approved drugs for achondroplasia, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Drugs in development for achondroplasia
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- Modified recombinant human C-type natriuretic peptideBMN 111Phase 32 trials
BioMarin · Achondroplasia
- BMN 333Phase 31 trial
BioMarin · Achondroplasia
- KK8398Phase 31 trial
Kyowa Kirin Co., Ltd. · Achondroplasia
- DabogratinibTYRA-300Phase 24 trials
Tyra Biosciences, Inc · FGFR3 Gene Mutation, FGFR3 Gene Alteration, Achondroplasia
- ABSK061Phase 22 trials
Abbisko Therapeutics Co, Ltd · HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- Combination of NavepegritidePhase 21 trial
Ascendis Pharma Growth Disorders A/S · Achondroplasia
More on achondroplasia: recruiting trials · published research
Related in rare and genetic disease: Transthyretin amyloidosis · Hereditary angioedema · Fabry disease · Gaucher disease · Pompe disease · Phenylketonuria (PKU)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.